Episode notes
We talk to Richard Klinghoffer Ph.D., CEO and CSO of Presage Biosciences. Presage’s Comparative In Vivo Oncology (CIVO™) system administers micro-doses of multiple drugs and/or combinations simultaneously to distinct trackable positions within a solid tumor. The tumor is then resected and analyzed to understand the microenvironment response to each spatially defined region of exposure. This is in a bid to evaluate early investigational stage cancer drugs in the most relevant context – the cancer patient, without exposing the patient to toxic effects associated with systemic delivery. We talk to Rich about his journey to Presage, the nuances between running a company and running experiments, and the field of drug development and how spatial instruments like the GeoMx DSP will influence that endeavor.
This podcast includes information reg ...